Skip to main content

Table 3 Cholangiocarcinoma: prior therapy , concurrent chemotherapy, and treatment duration

From: HER2/neu-directed therapy for biliary tract cancer

Pt # Sites of disease Prior therapy HER2/neu test HER2/neu therapy Concurrent therapy Duration of therapy Overall survival Best response
1 Liver, mediastinum, Lung Gemcitabine folfirinox Mutation (NGS) V777L Trastuzumab Gemcitabine, docetaxel 19 29 PD
2 Liver, peritoneum, lung Gemcitabine + cisplatin ERBB2 amp NGS Trastuzumab FOLFOX 14 25 PD
3 Mediastinum Gemcitabine + cisplatin, FOLFIRI, GTX ERBB2 NGS S310F Trastuzumab FOLFOX 7 7 PD
4 Liver, lung Nil AMPLIFIED (FISH) Trastuzumab   6 8 PD
5 Lung, liver, bones Gemcitabine + cisplatin AMPLIFIED (FISH) Trastuzumab   10 12 PD
  1. HER2-positive tumors (IHC 3+, FISH HER2/centromere 17 ratio ≥2.0 or both
  2. SD stable disease, PD progressive disease, CR complete response, PR partial response